Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
Open Access
- 4 September 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 55 (11), 2929-2937
- https://doi.org/10.1007/s00125-012-2668-0
Abstract
Aims/hypothesis Current drug labels for thiazolidinediones (TZDs) warn of increased fractures, predominantly for distal fractures in women. We examined whether exposure to TZDs affects hip fracture in women and men and compared the risk to that found with other drugs used in diabetes. Methods Using a nationwide database of prescriptions, hospital admissions and deaths in those with type 2 diabetes in Scotland we calculated TZD exposure among 206,672 individuals. Discrete-time failure analysis was used to model the effect of cumulative drug exposure on hip fracture during 1999–2008. Results There were 176 hip fractures among 37,479 exposed individuals. Hip fracture risk increased with cumulative exposure to TZD: OR per year of exposure 1.18 (95% CI 1.09, 1.28; p = 3 × 10−5), adjusted for age, sex and calendar month. Hip fracture increased with cumulative exposure in both men (OR 1.20; 95% CI 1.03, 1.41) and women (OR 1.18; 95% CI 1.07, 1.29) and risks were similar for pioglitazone (OR 1.18) and rosiglitazone (OR 1.16). The association was similar when adjusted for exposure to other drugs for diabetes and for other potential confounders. There was no association of hip fracture with cumulative exposure to sulfonylureas, metformin or insulin in this analysis. The 90-day mortality associated with hip fractures was similar in ever-users of TZD (15%) and in never-users (13%). Conclusions/interpretation Hip fracture is a severe adverse effect with TZDs, affecting both sexes; labels should be changed to warn of this. The excess mortality is at least as much as expected from the reported association of pioglitazone with bladder cancer.Keywords
This publication has 25 references indexed in Scilit:
- Risk of fractures in patients with multiple sclerosisNeurology, 2012
- Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort studyDiabetologia, 2012
- Self-Controlled Case Series Analysis With Event-Dependent Observation PeriodsJournal of the American Statistical Association, 2011
- Thiazolidinediones and Fractures: Evidence from Translating Research into Action for DiabetesJournal of Clinical Endocrinology & Metabolism, 2010
- Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary OsteoporosisCurrent Osteoporosis Reports, 2010
- Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 2010
- Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScoresBMJ, 2009
- The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series StudyPLoS Medicine, 2009
- A Cohort Study of Thiazolidinediones and Fractures in Older Adults with DiabetesJournal of Clinical Endocrinology & Metabolism, 2009
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisCMAJ : Canadian Medical Association Journal, 2009